NIH Considers Exclusive Patent License for Autoimmune Disease Immunotherapy
February 13, 2026
February 13, 2026
WASHINGTON, Feb. 13 (TNSFR) -- The U.S. Department of Health and Human Services National Institutes of Health announced that it is contemplating the grant of a worldwide exclusive patent license to Kyverna Therapeutics Inc., Emeryville, California. The proposed agreement would allow the Emeryville, California-based company to practice specific inventions related to anti-CD19 chimeric antigen receptor (CAR)-based immunotherapies.
The intellectual property involves a large family of p . . .
The intellectual property involves a large family of p . . .